Drug intelligence / Profile preview

WTX301

Development stage: Preclinical
Lead developer: Wntrix
Modality: Small Molecules

Overview

WTX301 is a preclinical-stage small molecule therapeutic candidate being developed by Wntrix for the treatment of various solid tumors, including kidney cancer, lung cancer, and skin cancer. Wntrix focuses on the development of modulators of the Wnt signaling pathway, a key driver in oncogenesis and tumor progression. WTX301 is designed to target dysregulated Wnt signaling to inhibit tumor growth and survival. The drug is currently undergoing preclinical evaluation to support potential future clinical development.

Beyond the preview

Go deeper on WTX301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX301.

Explore the full profile